Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Alexander Burnett

Concepts (192)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Endometrial Neoplasms
7
2020
155
1.240
Why?
Uterine Cervical Neoplasms
11
2013
285
1.210
Why?
Gynecologic Surgical Procedures
4
2009
29
1.010
Why?
Whole-Body Irradiation
2
2014
163
0.970
Why?
Lymph Node Excision
4
2011
136
0.810
Why?
Metformin
2
2020
68
0.760
Why?
Hypoglycemic Agents
2
2020
188
0.700
Why?
Interleukin-11
2
2013
9
0.620
Why?
Neoplasm Recurrence, Local
3
2016
597
0.570
Why?
2-Pyridinylmethylsulfinylbenzimidazoles
1
2014
22
0.550
Why?
Prescription Drugs
1
2014
39
0.530
Why?
Uterine Neoplasms
7
2007
65
0.530
Why?
Proton Pump Inhibitors
1
2014
91
0.510
Why?
Radiation Tolerance
1
2014
90
0.510
Why?
Robotics
2
2010
44
0.480
Why?
Radiation-Protective Agents
1
2013
115
0.470
Why?
Obesity
2
2016
1180
0.460
Why?
Laparoscopy
4
2010
184
0.450
Why?
Organotechnetium Compounds
1
2011
8
0.440
Why?
Lymphedema
1
2011
43
0.420
Why?
Vulvar Neoplasms
1
2011
54
0.420
Why?
Lower Extremity
1
2011
90
0.410
Why?
Radiopharmaceuticals
1
2011
254
0.390
Why?
Cystadenocarcinoma, Papillary
5
2006
16
0.380
Why?
Carcinoma, Squamous Cell
2
2011
400
0.370
Why?
Fertility
2
2009
37
0.340
Why?
Cervix Uteri
1
2006
48
0.300
Why?
Topotecan
1
2005
19
0.290
Why?
Adenocarcinoma
1
2009
435
0.280
Why?
Genital Neoplasms, Female
1
2004
39
0.270
Why?
Polyethylene Glycols
1
2005
97
0.270
Why?
Female
29
2020
28868
0.260
Why?
Postoperative Complications
1
2011
1077
0.250
Why?
Ovarian Neoplasms
4
2014
447
0.250
Why?
Doxorubicin
1
2005
266
0.240
Why?
Adult
18
2016
14342
0.240
Why?
Antineoplastic Combined Chemotherapy Protocols
3
2007
1025
0.230
Why?
Lymph Nodes
1
2004
289
0.230
Why?
Gene Expression Regulation, Neoplastic
6
2011
895
0.220
Why?
Aged
15
2016
10444
0.220
Why?
Middle Aged
17
2020
13652
0.220
Why?
Humans
31
2020
52749
0.210
Why?
Aged, 80 and over
5
2016
3637
0.200
Why?
Intestines
2
2013
216
0.190
Why?
Neoplasm Staging
7
2006
807
0.190
Why?
Carcinoma
2
2011
161
0.170
Why?
Dendritic Cells
3
2014
151
0.160
Why?
Cancer Vaccines
3
2014
105
0.160
Why?
Cell Proliferation
2
2020
1128
0.160
Why?
Antineoplastic Agents
2
2007
1287
0.160
Why?
Cystadenocarcinoma, Serous
3
2005
70
0.160
Why?
Enterotoxins
2
2007
12
0.160
Why?
Aromatase Inhibitors
2
2007
17
0.150
Why?
Kruppel-Like Transcription Factors
2
2020
85
0.150
Why?
Kallikreins
2
2006
21
0.150
Why?
Nitriles
2
2007
68
0.150
Why?
Receptor, erbB-2
2
2005
84
0.140
Why?
Triazoles
2
2007
123
0.140
Why?
Lethal Dose 50
1
2014
20
0.140
Why?
Mice
4
2014
6399
0.140
Why?
Neoplasms
1
2005
1250
0.140
Why?
Medical Oncology
2
2006
108
0.140
Why?
Indoleamine-Pyrrole 2,3,-Dioxygenase
1
2014
16
0.140
Why?
Ascites
1
2014
26
0.130
Why?
Hydrogen-Ion Concentration
1
2014
196
0.130
Why?
Hematopoiesis
1
2014
85
0.130
Why?
Safety
1
2014
103
0.130
Why?
Stomach
1
2014
70
0.130
Why?
Survival Analysis
2
2013
800
0.130
Why?
Spectrometry, Fluorescence
1
2013
57
0.120
Why?
Cervical Intraepithelial Neoplasia
1
2013
42
0.120
Why?
Carcinoma, Endometrioid
2
2010
41
0.120
Why?
Retrospective Studies
3
2016
6037
0.120
Why?
CD4-Positive T-Lymphocytes
1
2014
188
0.120
Why?
Administration, Oral
1
2013
481
0.120
Why?
Incidence
1
2016
1094
0.120
Why?
Papillomaviridae
3
2013
106
0.110
Why?
Animals
5
2014
14805
0.100
Why?
Cytokines
1
2014
700
0.100
Why?
Cerclage, Cervical
1
2009
8
0.100
Why?
Obesity, Morbid
1
2010
83
0.100
Why?
Arkansas
1
2016
2179
0.100
Why?
Estrogens
1
2011
257
0.090
Why?
Genes, erbB-2
2
2005
8
0.090
Why?
Treatment Outcome
3
2011
5634
0.090
Why?
Gene Amplification
2
2005
59
0.090
Why?
Carcinoma, Papillary
2
2005
67
0.090
Why?
Leiomyosarcoma
1
2007
24
0.090
Why?
Clostridium perfringens
1
2007
5
0.080
Why?
Carcinosarcoma
1
2007
17
0.080
Why?
Intestinal Diseases
1
2007
49
0.080
Why?
Melanoma
1
2011
318
0.080
Why?
Membrane Proteins
2
2007
389
0.080
Why?
Male
4
2014
28268
0.080
Why?
Radiation Injuries, Experimental
1
2007
129
0.080
Why?
Infertility, Female
1
2006
22
0.080
Why?
Endometrium
2
2020
75
0.080
Why?
Vagina
1
2006
46
0.070
Why?
Oncogene Proteins, Viral
1
2005
59
0.070
Why?
Dysgerminoma
1
2004
3
0.070
Why?
Fellowships and Scholarships
1
2006
125
0.070
Why?
Medroxyprogesterone Acetate
1
2004
5
0.070
Why?
Immunotherapy, Adoptive
1
2005
81
0.070
Why?
Retroperitoneal Space
1
2004
29
0.070
Why?
Gynecology
1
2004
43
0.070
Why?
Patient Selection
1
2006
295
0.070
Why?
Interleukin-6
1
2005
318
0.060
Why?
Lymphatic Metastasis
1
2004
255
0.060
Why?
Drug Therapy, Combination
1
2005
438
0.060
Why?
Immunotherapy
1
2005
247
0.060
Why?
Immunohistochemistry
4
2007
1144
0.060
Why?
Adolescent
4
2013
6849
0.060
Why?
Antibodies, Monoclonal
1
2007
565
0.060
Why?
DNA-Binding Proteins
1
2005
512
0.060
Why?
Education, Medical, Graduate
1
2004
217
0.060
Why?
Cells, Cultured
3
2014
1839
0.060
Why?
Lung Neoplasms
1
2007
598
0.060
Why?
Preoperative Period
1
2020
66
0.050
Why?
PTEN Phosphohydrolase
1
2020
69
0.050
Why?
Receptors, Progesterone
1
2020
89
0.050
Why?
Gene Expression Profiling
1
2005
1119
0.050
Why?
Estrogen Receptor alpha
1
2020
110
0.050
Why?
Cell Line, Tumor
3
2007
1505
0.040
Why?
Pilot Projects
1
2020
803
0.040
Why?
Claudin-3
2
2007
4
0.040
Why?
Claudin-4
2
2007
5
0.040
Why?
Mice, SCID
2
2007
201
0.040
Why?
Lymphocyte Activation
2
2007
214
0.040
Why?
Hysterectomy
2
2007
68
0.040
Why?
Enzyme-Linked Immunosorbent Assay
2
2006
317
0.040
Why?
In Situ Hybridization, Fluorescence
2
2005
274
0.030
Why?
Coculture Techniques
1
2014
163
0.030
Why?
p38 Mitogen-Activated Protein Kinases
1
2014
101
0.030
Why?
Human Umbilical Vein Endothelial Cells
1
2014
100
0.030
Why?
Optics and Photonics
1
2013
14
0.030
Why?
Uterine Cervical Dysplasia
1
2013
18
0.030
Why?
Drug Resistance, Neoplasm
2
2005
297
0.030
Why?
Antigens, Neoplasm
1
2014
169
0.030
Why?
Combined Modality Therapy
2
2007
713
0.030
Why?
Apoptosis
1
2020
1356
0.030
Why?
Spectrum Analysis
1
2013
77
0.030
Why?
Prospective Studies
2
2013
2444
0.030
Why?
Early Detection of Cancer
1
2013
138
0.030
Why?
Papillomavirus Infections
1
2013
159
0.030
Why?
Gene Silencing
1
2011
131
0.030
Why?
RNA, Messenger
2
2005
1276
0.030
Why?
Prognosis
2
2005
2104
0.020
Why?
Antibody-Dependent Cell Cytotoxicity
1
2007
15
0.020
Why?
Neoplasm Transplantation
1
2007
94
0.020
Why?
Antineoplastic Agents, Hormonal
1
2007
55
0.020
Why?
Mast Cells
1
2007
71
0.020
Why?
Remission Induction
1
2007
223
0.020
Why?
Transforming Growth Factor beta
1
2007
169
0.020
Why?
Lymphocytes
1
2007
174
0.020
Why?
Hypersensitivity, Delayed
1
2005
21
0.020
Why?
Papillomavirus E7 Proteins
1
2005
35
0.020
Why?
Sampling Studies
1
2005
42
0.020
Why?
Recombinant Proteins
1
2007
596
0.020
Why?
Antigens, Viral
1
2005
57
0.020
Why?
Paraffin Embedding
1
2005
58
0.020
Why?
Injections, Intraperitoneal
1
2005
67
0.020
Why?
Probability
1
2005
187
0.020
Why?
Intestinal Mucosa
1
2007
292
0.020
Why?
Antibodies, Monoclonal, Humanized
1
2007
232
0.020
Why?
Statistics, Nonparametric
1
2005
245
0.020
Why?
Feasibility Studies
1
2006
406
0.020
Why?
Carboplatin
1
2004
54
0.020
Why?
Biopsy, Needle
1
2005
205
0.020
Why?
Etoposide
1
2004
89
0.020
Why?
Xenograft Model Antitumor Assays
1
2005
213
0.020
Why?
B-Lymphocytes
1
2005
187
0.020
Why?
Chemotherapy, Adjuvant
1
2004
133
0.020
Why?
Receptors, Cell Surface
1
2005
138
0.020
Why?
Tumor Cells, Cultured
1
2005
522
0.020
Why?
Flow Cytometry
1
2007
583
0.020
Why?
Proportional Hazards Models
1
2005
464
0.020
Why?
Polymerase Chain Reaction
1
2005
552
0.020
Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2005
716
0.020
Why?
Oligonucleotide Array Sequence Analysis
1
2005
500
0.020
Why?
Rats, Sprague-Dawley
1
2007
1811
0.020
Why?
T-Lymphocytes
1
2005
339
0.020
Why?
Sensitivity and Specificity
1
2005
970
0.020
Why?
Young Adult
1
2013
4292
0.020
Why?
Clinical Competence
1
2006
444
0.010
Why?
Case-Control Studies
1
2006
1262
0.010
Why?
Disease-Free Survival
1
2003
521
0.010
Why?
Survival Rate
1
2005
1015
0.010
Why?
Regression Analysis
1
2003
476
0.010
Why?
Age Factors
1
2005
1267
0.010
Why?
Rats
1
2007
3608
0.010
Why?
Risk Assessment
1
2005
1413
0.010
Why?
Child
1
2004
6864
0.010
Why?
Burnett's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description